A Safety and Efficacy Trial of Docetaxel With or Without XH1 in Non-small Cell Lung Cancer (NSCLC) Patients
Status:
Unknown status
Trial end date:
2019-02-01
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized, multicenter clinical study designed to evaluate its safety
and efficacy by using Docetaxel with or without Traditional Chinese Medicine XH1 in patients
with Stage ⅢB-Ⅳ Non-small Cell Lung Cancer (NSCLC) who failed with first-line Chemotherapy.
The primary outcome measure includes progression-free survival (PFS) after treatment.
Secondary outcome measures include collecting biomarkers before and during treatment, overall
survival (OS), objective response rate (ORR), disease control rate (DCR), and patient's
quality of life.